Peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C, and vitamin B6 during continuous ambulatory peritoneal dialysis. 1998

M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
Nephrological Clinic, University Hospital of L. Pasteur, Kosice, Slovak Republic.

The peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C, and vitamin B6 in 32 patients during continuous ambulatory peritoneal dialysis (CAPD) using peritoneal dialysis solutions containing 1.5% or 2.5% glucose were examined. The plasma level of oxalic acid was significantly elevated in all patients, plasma vitamin C was in the normal range or in the upper margin of the normal range, and plasma vitamin B6 was in the normal range. The peritoneal clearance of oxalic acid was significantly lower, and the peritoneal clearance of vitamin B6 was the lowest in comparison to the peritoneal clearance of urea. With the exception of vitamin B6, the peritoneal clearance and peritoneal transfer of the examined parameters increased using the dialysis solution containing 2.5% glucose. We found direct relationships between the plasma levels of oxalic acid and creatinine as well as plasma vitamin C and between the peritoneal transfer of oxalic acid and the peritoneal transfer of vitamin C as well as vitamin B6. The significant hyperoxalemia of our patients was found to persist despite the relatively high peritoneal transfer of oxalic acid during CAPD. These results suggest that CAPD is not a method effective enough for permanent reduction of the plasma levels of oxalic acid.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D011736 Pyridoxine The 4-methanol form of VITAMIN B 6 which is converted to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). Pyridoxin,Pyridoxine Hydrochloride,Pyridoxol,Pyridoxol Hydrochloride,Rodex
D004044 Dietary Proteins Proteins obtained from foods. They are the main source of the ESSENTIAL AMINO ACIDS. Proteins, Dietary,Dietary Protein,Protein, Dietary
D004232 Diuretics Agents that promote the excretion of urine through their effects on kidney function. Diuretic,Diuretic Effect,Diuretic Effects,Effect, Diuretic,Effects, Diuretic
D005260 Female Females
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
January 1985, Nephron,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
June 1985, Drug intelligence & clinical pharmacy,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
November 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
January 1988, Nephron,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
January 1980, Transactions - American Society for Artificial Internal Organs,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
September 1997, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
January 1980, Annals of internal medicine,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
June 1984, Kidney international,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
January 2019, Nefrologia,
M Mydlík, and K Derzsiová, and J Svác, and P Dlhopolcek, and E Zemberová
January 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
Copied contents to your clipboard!